https://prn1371inhibitor.com/c....omputational-review-
INTRODUCTION Endometrial cancer (EC) known prognostic facets aren't enough to predict either outcome or recurrence rate/site to research EC recurrence habits according to ESMO-ESGO-ESTRO risk classes, could possibly be beneficial for a more tailored adjuvant therapy and follow-up schedule. TECHNIQUES 758 women identified as having EC, and a 5-years followup, had been enrolled they were divided in to the ESMO-ESGO-ESTRO risk clas
Like
Comment
Share
